Drug repositioning for personalized medicine

Genome Medicine

Volumn 4, Issue 3, 2012, Pages

  Li, Yvonne Y ^a   Jones, Steven J M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cancer; Computational drug design; Drug discovery; High throughput screening; Orphan diseases; Personalized medicine; Repositioning; Repurposing

Indexed keywords

ABC TRANSPORTER; AMFEBUTAMONE; BEVACIZUMAB; CISAPRIDE; CLOZAPINE; CRIZOTINIB; CYTOCHROME P450 2D6; DULOXETINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MINOXIDIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NALTREXONE; NELFINAVIR; PRESCRIPTION DRUG; PROTEIN KINASE B; PROTEIN RET; RITUXIMAB; SILDENAFIL; SUNITINIB; THALIDOMIDE; TRANSCRIPTOME; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ANGINA PECTORIS; BRAIN PSEUDOTUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL ASSAY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DATA BASE; DEPRESSION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MANUFACTURE; DRUG REPOSITIONING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FIBROMYALGIA; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HAIR LOSS; HEART VENTRICLE ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEPROSY; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR DOCKING; MORNING SICKNESS; MULTIPLE CANCER; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NEUROENDOCRINE TUMOR; NONHUMAN; OBESITY; ONCOGENE; ONCOGENE K RAS; OPIATE ADDICTION; PANCREAS TUMOR; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE; REVIEW; RHABDOMYOSARCOMA; SCHIZOPHRENIA; STOMACH CANCER; STRESS INCONTINENCE; THYROID CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84858978535     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm326     Document Type: Review

References (132)

1. Lawrence S. Drug output slows in 2006. Nat Biotechnol 2007, 25:1073.
2. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683. 10.1038/nrd1468, 15286734.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715. 10.1038/nrd1470, 15286737.
4. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009, 8:959-968. 10.1038/nrd2961, 19949401.
5. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-214.
6. Light DW, Warburnt R. Demythologizing the high costs of pharmaceutical research. Biosoci 2011, 6:34-50.
7. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011, 10:897-898. 10.1038/nrd3600, 22129984.
8. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009, 22:119-125. 10.1358/dnp.2009.22.2.1343228, 19330170.
9. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007, 448:645-646. 10.1038/448645a, 17687303.
10. Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg 2011, 8:131.
11. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011, 57:153-160. 10.4103/0022-3859.81870, 21654146.
12. Voelker R. International group seeks to dispel incontinence "taboo". JAMA 1998, 280:951-953. 10.1001/jama.280.11.951, 9749464.
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056. 10.1056/NEJM200104053441404, 11287975.
14. Druker B. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004, 91:1-30.
15. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566. 10.1038/nature05945, 17625570.
16. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13:5183-5194. 10.1158/1078-0432.CCR-07-0161, 17785575.
17. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10:61-71. 10.1016/S1470-2045(08)70334-6, 19111246.
18. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336. 10.1038/nbt1068, 15711537.
19. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132. 10.1038/nbt1358, 18183025.
20. FDA Okays Everolimus for Rare Type of Pancreatic Cancer. , http://www.medscape.com/viewarticle/742274
21. Schuessler B. What do we know about duloxetine's mode of action? Evidence from animals to humans. BJOG 2006, 113(Suppl 1):5-9.
22. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med 2009, 122(12 Suppl):S44-S55.
23. Marcus DA. Duloxetine use in painful conditions. Expert Opin Pharmacother 2011, 12:1333-1340. 10.1517/14656566.2011.580739, 21548724.
24. Bradley D. Why big pharma needs to learn the three 'R's. Nat Rev Drug Discov 2005, 4:446. 10.1038/nrd1766, 15959947.
25. Frantz S. Drug discovery: playing dirty. Nature 2005, 437:942-943. 10.1038/437942a, 16222266.
26. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8:3034-3038.
27. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 2011, 10:328-329.
28. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011, 10:87. 10.1038/nrd3375, 21283095.
29. The bitterest pill. Nature 2006, 444:532-533.
30. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
31. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
32. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323. 10.1056/NEJMoa0802885, 19038878.
33. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. Ann Allergy Asthma Immunol 2008, 101:1-8. quiz 8-11, 50, 10.1016/S1081-1206(10)60826-5, 18681077.
34. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity?. Diabetes 2007, 56:1189-1197. 10.2337/db06-0880, 17322478.
35. Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol 2006, 13:115-120. 10.1016/j.spen.2006.06.007, 17027861.
36. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172. 10.1056/NEJM199907153410306, 10403855.
37. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780. 10.1016/j.ejca.2010.04.002, 2888755, 20418096.
38. Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2009, 21:5-10. 10.1097/CCO.0b013e32831ba0b3, 19125012.
39. Ross JS. Saving lives with accurate HER2 testing. Am J Clin Pathol 2010, 134:183-184. 10.1309/AJCP6VZ8YHMZNNED, 20660318.
40. Lefferts JA, Tsongalis GJ, Suriawinata AA, Funkhouser WK, Ladanyi M, Nowak JA, Pipas JM. KRAS mutation detection: a new look at an old gene. Clin Chem 2010, 56:698-701. 10.1373/clinchem.2009.138735, 20207769.
41. Drews J. Drug discovery: a historical perspective. Science 2000, 287:1960-1964. 10.1126/science.287.5460.1960, 10720314.
42. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011, 10:811-812. 10.1038/nrd3579, 22037033.
43. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491. 10.1126/science.286.5439.487, 10521338.
44. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002, 3:89-98. 10.1517/14622416.3.1.89, 11966406.
45. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83:160-166. 10.1038/sj.clpt.6100367, 2752373, 17882159.
46. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127. 10.2217/14622416.9.1.105, 18154452.
47. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203. 10.1126/science.1200609, 3144496, 21252315.
48. Altman RB. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet 2007, 39:426. 10.1038/ng0407-426, 3203536, 17392795.
49. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537. 10.1126/science.286.5439.531, 10521349.
50. Anonymous Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat Rev Drug Discov 2010, 9:423. Anonymous.
51. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N, Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J, Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol 2010, 11:R82. 10.1186/gb-2010-11-8-r82, 2945784, 20696054.
52. Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011, 305:1577-1584. 10.1001/jama.2011.497, 3156695, 21505136.
53. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011, 13:255-262. 10.1097/GIM.0b013e3182088158, 21173700.
54. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011, 3:111ra121. 10.1126/scitranslmed.3003161, 22133722.
55. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, Han B, Zhang P, Chen Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2011, 40:D1128-D1136. 3245130, 21948793.
56. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480. 10.1038/nrc2394, 18469827.
57. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006, 24:805-815. 10.1038/nbt1228, 16841068.
58. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst 2009, 5:1051-1057. 10.1039/b905821b, 19668871.
59. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934. 10.1126/science.1075762, 12471243.
60. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3:353-359. 10.1038/nrd1346, 15060530.
61. Du L, Li M, You Q, Xia L. A novel structure-based virtual screening model for the hERG channel blockers. Biochem Biophys Res Commun 2007, 355:889-894. 10.1016/j.bbrc.2007.02.068, 17331468.
62. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019. 10.1200/JCO.2010.33.5091, 21502544.
63. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008, 15:422-432. 10.2174/092986708783503212, 18288997.
64. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H. Cellular targets of gefitinib. Cancer Res 2005, 65:379-382.
65. Zeder-Lutz G, Choulier L, Besse M, Cousido-Siah A, Figueras FX, Didier B, Jung ML, Podjarny A, Altschuh D. Validation of surface plasmon resonance screening of a diverse chemical library for the discovery of protein tyrosine phosphatase 1b binders. Anal Biochem 2011, 421:417-427.
66. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci USA 2007, 104:19023-19028. 10.1073/pnas.0709695104, 2141901, 18024584.
67. Antczak C, Kloepping C, Radu C, Genski T, Muller-Kuhrt L, Siems K, de Stanchina E, Abramson DH, Djaballah H. Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. Invest Ophthalmol Vis Sci 2009, 50:3065-3073. 10.1167/iovs.08-3158, 19151399.
68. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafstrom RC, Perala M, Kallioniemi O. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009, 15:6070-6078. 10.1158/1078-0432.CCR-09-1035, 19789329.
69. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Feau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011, 20:384-399. 10.1016/j.ccr.2011.08.013, 21907928.
70. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939, 17008526.
71. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010, 107:14621-14626. 10.1073/pnas.1000138107, 2930479, 20679242.
72. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011, 3:80ps16. 10.1126/scitranslmed.3001862, 21525397.
73. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010, 85:1-18. 10.1016/j.antiviral.2009.10.002, 2815149, 20018391.
74. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature 2009, 462:175-181. 10.1038/nature08506, 2784146, 19881490.
75. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009, 5:e1000423. 10.1371/journal.pcbi.1000423, 2699117, 19578428.
76. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266. 10.1126/science.1158140, 18621671.
77. Chen YZ, Zhi DG. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43:217-226. 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO;2-G, 11276090.
78. Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One 2010, 5:e9568. 10.1371/journal.pone.0009568, 2833192, 20221449.
79. Li H, Gao Z, Kang L, Zhang H, Yang K, Yu K, Luo X, Zhu W, Chen K, Shen J, Wang X, Jiang H. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006, 34:W219-W224. 10.1093/nar/gkl114, 1538869, 16844997.
80. Li L, Bum-Erdene K, Baenziger PH, Rosen JJ, Hemmert JR, Nellis JA, Pierce ME, Meroueh SO. BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome. Nucleic Acids Res 2010, 38:D765-D773. 10.1093/nar/gkp852, 2808957, 19923229.
81. Li YY, An J, Jones SJ. A computational approach to finding novel targets for existing drugs. PLoS Comput Biol 2011, 7:e1002139. 10.1371/journal.pcbi.1002139, 3164726, 21909252.
82. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model 2009, 49:2044-2055. 10.1021/ci9001876, 19708682.
83. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011, 3:96ra76. 10.1126/scitranslmed.3002648, 21849664.
84. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010, 31:115-123. 10.1016/j.tips.2009.11.006, 20117850.
85. Kotelnikova E, Yuryev A, Mazo I, Daraselia N. Computational approaches for drug repositioning and combination therapy design. J Bioinform Comput Biol 2010, 8:593-606. 10.1142/S0219720010004732, 20556864.
86. Ha S, Seo YJ, Kwon MS, Chang BH, Han CK, Yoon JH. IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics 2008, 24:1413-1415. 10.1093/bioinformatics/btn138, 18417489.
87. Frijters R, van Vugt M, Smeets R, van Schaik R, de Vlieg J, Alkema W. Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol 2010, 6:e1000943. 10.1371/journal.pcbi.1000943, 2944780, 20885778.
88. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006, 34:D668-D672. 10.1093/nar/gkj067, 1347430, 16381955.
89. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006, 34:D354-D357. 10.1093/nar/gkj102, 1347464, 16381885.
90. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, Ahmed J, Urdiales EG, Gewiess A, Jensen LJ, Schneider R, Skoblo R, Russell RB, Bourne PE, Bork P, Preissner R. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008, 36:D919-D922. 2238858, 17942422.
91. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011, 12:303-311. 10.1093/bib/bbr013, 21690101.
92. Haupt VJ, Schroeder M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform 2011, 12:312-326. 10.1093/bib/bbr011, 21441562.
93. Haffner ME. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med 2006, 354:445-447. 10.1056/NEJMp058317, 16452556.
94. Cote TR, Xu K, Pariser AR. Accelerating orphan drug development. Nat Rev Drug Discov 2010, 9:901-902. 10.1038/nrd3340, 21119719.
95. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010, 9:921-929. 10.1038/nrd3275, 21060315.
96. Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform 2011, 12:346-356. 10.1093/bib/bbr021, 21504985.
97. Xu K, Cote TR. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform 2011, 12:341-345. 10.1093/bib/bbr006, 21357612.
98. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011, 8:587-596. 10.1038/nrclinonc.2011.121, 21862978.
99. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185. 10.1038/ng.518, 2850970, 20081860.
100. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066. 10.1056/NEJMoa0903840, 3201812, 19657110.
101. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558. 10.1126/science.1204040, 21436442.
102. Sinha G. Academia's $1,000 genome. Nat Biotechnol 2011, 29:960-960a.
103. Hallberg B, Palmer RH. Crizotinib - latest champion in the cancer wars?. N Engl J Med 2010, 363:1760-1762. 10.1056/NEJMe1010404, 20979477.
104. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726. 10.1200/JCO.20.3.719, 11821453.
105. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510. 10.1038/nature10738, 22237025.
106. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006, 8:215. 10.1186/bcr1612, 1797036, 17096862.
107. Solit D, Sawyers CL. Drug discovery: How melanomas bypass new therapy. Nature 2010, 468:902-903. 10.1038/468902a, 21164474.
108. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17. 10.1126/scitranslmed.3003316, 22277784.
109. Batist G, Wu JH, Spatz A, Miller WH, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol 2011, 2:59. 3186943, 22007174.
110. Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A, Margerison S, Melo JV, Goldman JM, Apperley JF, Kaeda J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20:658-663. 10.1038/sj.leu.2404137, 16467863.
111. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 3143360, 21107323.
112. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390. 10.1038/nature10662, 22113612.
113. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009, 15:7519-7527. 10.1158/1078-0432.CCR-09-1068, 20008852.
114. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338. 10.1182/blood-2006-02-004580, 1895563, 16772610.
115. Kasaian K, Jones SJ. A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncol 2011, 7:873-894. 10.2217/fon.11.63, 21732758.
116. Gross M. Riding the wave of biological data. Curr Biol 2011, 21:R204-R206. 10.1016/j.cub.2011.03.009, 21429838.
117. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007, 35:W169-W175. 10.1093/nar/gkm415, 1933169, 17576678.
118. Sakharkar MK, Li P, Zhong Z, Sakharkar KR. Quantitative analysis on the characteristics of targets with FDA approved drugs. Int J Biol Sci 2007, 4:15-22. 2140153, 18167532.
119. Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006, 11:607-615. 10.1016/j.drudis.2006.05.014, 1524586, 16793529.
120. Parker CN, Bajorath J. Towards unified compound screening strategies: a critical evaluation of error sources in experimental and virtual high-throughput screening. QSAR Combinatorial Sci 2006, 25:1153-1161.
121. Crisman TJ, Parker CN, Jenkins JL, Scheiber J, Thoma M, Kang ZB, Kim R, Bender A, Nettles JH, Davies JW, Glick M. Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data. J Chem Inf Model 2007, 47:1319-1327. 10.1021/ci6005504, 17608469.
122. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006, 11:580-594. 10.1016/j.drudis.2006.05.012, 16793526.
123. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006, 24:167-175. 10.1038/nbt1186, 16465162.
124. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?. Curr Treat Options Oncol 2011, 12:96-106. 10.1007/s11864-010-0135-z, 21274667.
125. FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors. GEN News Highlights 2011, , http://www.genengnews.com/gen-news-highlights/fda-expands-sutent-label-to-include-pancreatic-neuroendocrine-tumors/81245191/
126. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009, 10:1069-1081. 10.1517/14656560902775750, 19364254.
127. Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab 2011, 13:490-497. 10.1111/j.1463-1326.2010.01353.x, 21205125.
128. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012, 366:489-491. 10.1056/NEJMp1114866, 22256780.
129. Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther 2011, 4:21-26. 3084304, 21552412.
130. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5:689-702. 10.1038/nrd2030, 16883306.
131. Delbaldo C, Faivre S, Dreyer C, Raymond E. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Ther Adv Med Oncol 2012, 4:9-18. 10.1177/1758834011428147, 3244202, 22229044.
132. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008, 27:111-135. 10.1080/08830180801911339, 18437602.